In vitro and in vivo protection against enterovirus 71 by an antisense phosphorothioate oligonucleotide

[1]  Man Tsuey Tse.  Regulatory watch: Antisense approval provides boost to the field , 2013, Nature Reviews Drug Discovery.

[2]  Kuo-Feng Weng,et al.  Viral and host factors that contribute to pathogenicity of enterovirus 71. , 2012, Future microbiology.

[3]  H. Kung,et al.  The virology and developments toward control of human enterovirus 71 , 2011, Critical reviews in microbiology.

[4]  D. A. Stein,et al.  Development of Peptide-Conjugated Morpholino Oligomers as Pan-Arenavirus Inhibitors , 2011, Antimicrobial Agents and Chemotherapy.

[5]  Daniel Jones.  The long march of antisense , 2011, Nature Reviews Drug Discovery.

[6]  Yan Jin,et al.  A large outbreak of hand, foot, and mouth disease caused by EV71 and CAV16 in Guangdong, China, 2009 , 2011, Archives of Virology.

[7]  M. Phoon,et al.  The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[8]  J. Chu,et al.  Developments towards antiviral therapies against enterovirus 71 , 2010, Drug Discovery Today.

[9]  Huaxi Xu,et al.  Epidemiology of hand, foot, and mouth disease and genotype characterization of Enterovirus 71 in Jiangsu, China. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[10]  S. Koike,et al.  Scavenger receptor B2 is a cellular receptor for enterovirus 71 , 2009, Nature Medicine.

[11]  D. A. Stein.  Inhibition of RNA virus infections with peptide-conjugated morpholino oligomers. , 2008, Current pharmaceutical design.

[12]  Ruiwen Zhang,et al.  Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? , 2008, Drug discovery today.

[13]  K. Ruxrungtham,et al.  HIV drug resistance transmission threshold survey in Bangkok, Thailand , 2008, Antiviral therapy.

[14]  Jing Yang,et al.  In vitro and in vivo Protection against the Highly Pathogenic H5N1 Influenza virus by an Antisense Phosphorothioate Oligonucleotide , 2008, Antiviral therapy.

[15]  V. Chow,et al.  Inhibition of Enterovirus 71 in Virus-infected Mice by RNA Interference. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  B. Davidson,et al.  Transvascular delivery of small interfering RNA to the central nervous system , 2007, Nature.

[17]  Xiuli Wu,et al.  A CpG oligodeoxynucleotide inducing anti‐coxsackie B3 virus activity in human peripheral blood mononuclear cells , 2007, FEMS immunology and medical microbiology.

[18]  C. Potera.  Antisense—down, but not out , 2007, Nature Biotechnology.

[19]  V. Chow,et al.  Enhanced potency and efficacy of 29-mer shRNAs in inhibition of Enterovirus 71. , 2007, Antiviral research.

[20]  C. Poh,et al.  Inhibition of enterovirus 71 in virus-infected mice by RNA interference. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  Jing Yang,et al.  Selection of antisense oligonucleotides based on multiple predicted target mRNA structures , 2006, BMC Bioinformatics.

[22]  V. Chow,et al.  RNA interference against enterovirus 71 infection. , 2005, Virology.

[23]  D. A. Stein,et al.  Inhibition of Flavivirus Infections by Antisense Oligomers Specifically Suppressing Viral Translation and RNA Replication , 2005, Journal of Virology.

[24]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[25]  S. Kung,et al.  Selective inhibition of enterovirus 71 replication by short hairpin RNAs. , 2004, Biochemical and biophysical research communications.

[26]  John J Rossi,et al.  Approaches for the sequence-specific knockdown of mRNA , 2003, Nature Biotechnology.

[27]  K. McKnight,et al.  RNA as a Target for Developing Antivirals , 2003, Antiviral chemistry & chemotherapy.

[28]  J. Kopeček,et al.  Antisense oligonucleotides delivered to the lysosome escape and actively inhibit the hepatitis B virus. , 2002, Bioconjugate chemistry.

[29]  M. Carbone,et al.  The Role of Environmental Carcinogens, Viruses, and Genetic , 2002, Cancer biology & therapy.

[30]  N. Dias,et al.  Antisense oligonucleotides: basic concepts and mechanisms. , 2002, Molecular cancer therapeutics.

[31]  P. McMinn,et al.  Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  T. Abe,et al.  Inhibitory effects of an antisense oligonucleotide in an experimentally infected mouse model of influenza A virus. , 2000, Biochemical and biophysical research communications.

[33]  Shin-Ru Shih,et al.  Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease , 1999, The Lancet.

[34]  Kow-Tong Chen,et al.  An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. , 1999, The New England journal of medicine.

[35]  T. Yeh,et al.  Neurologic complications in children with enterovirus 71 infection. , 1999, The New England journal of medicine.

[36]  Daniel C. Pevear,et al.  Activity of Pleconaril against Enteroviruses , 1999, Antimicrobial Agents and Chemotherapy.

[37]  K. Chua,et al.  Fatal enterovirus 71 encephalomyelitis. , 1998, The Journal of pediatrics.

[38]  Advances in CMV management: fomivirsen (Vitravene) approved. , 1998, Project Inform perspective.

[39]  M. Pallansch,et al.  Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. , 1995, Virus research.

[40]  T. Hyypiä,et al.  Molecular comparison of coxsackie A virus serotypes. , 1995, Virology.

[41]  L. Vance,et al.  The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus , 1995, Journal of virology.

[42]  M. Stephenson,et al.  Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[43]  E. H. Lennette,et al.  An apparently new enterovirus isolated from patients with disease of the central nervous system. , 1974, The Journal of infectious diseases.